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232
The vascular adventitia is a niche for multipotent and lineage-restricted resident progenitor cells, positive for Sca1 (stem 
cell antigen-1), cd34, c-kit, or Flk-11,2 and able to differentiate 
into the various cell types forming the vascular wall, including 
smooth muscle cells (SMCs), endothelial cells (EC), and mes-
enchymal cells. Recent evidence suggests that the vascular pro-
genitor cells, firstly identified in the adventitia of the aortic root 
of ApoE (apolipoprotein E)-deficient mice—a model of native 
atherosclerosis, contribute to vascular diseases and remodel-
ing.1 In vein graft and wire injury models, adventitial Sca1+ 
progenitor cells (AdvSca1) grafted on the perivascular side of 
the vessel, migrated to the neointima, newly expressed SMC 
markers, including SM22α (smooth muscle protein 22-alpha) 
and enhanced atherosclerotic progression.1,3 A recent study 
showed that 50% of neointimal SMCs of injured vessels were 
derived from adventitial mesenchymal stem cells.4 Reciprocally, 
Majesky et al5 demonstrated that a proportion of AdvSca1 cells 
originated in situ from differentiated medial SMCs and that 
after vascular injury, SMC-derived AdvSca1 cells expanded and 
were involved in adventitial remodeling. These findings impli-
cate that the vascular adventitial stem/progenitor cell population 
could play an important role in vascular diseases.
See cover image
AdvSca1 cells are preferentially specified toward an SMC 
fate in vitro,2 and collagen IV or PDGF-BB (platelet-derived 
growth factor-BB) strongly induced the expression of SMC 
genes, including αSMA (α-smooth muscle actin) and SM22α.1,6 
AdvSca1 cells showed to a lesser extent the potential to give 
rise to adipocytes, osteoblasts, and chondrocytes.6 When incu-
bated with VEGF (vascular endothelial growth factor), only 
a subset of AdvSca1 cells, also expressing αSMA, expressed 
EC marker cd31.2 Resveratrol promoted in vitro the differen-
tiation of AdvSca1 cells toward the endothelial lineage through 
inhibition of the β-catenin pathway. In vivo, a resveratrol-
enhanced diet also reduced neointima formation and promoted 
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Objective—Vascular adventitial Sca1+ (stem cell antigen-1) progenitor cells preferentially differentiate into smooth muscle cells, 
which contribute to vascular remodeling and neointima formation in vessel grafts. Therefore, directing the differentiation of 
Sca1+ cells toward the endothelial lineage could represent a new therapeutic strategy against vascular disease.
Approach and Results—We thus developed a fast, reproducible protocol based on the single-gene transfer of ETV2 (ETS 
variant 2) to differentiate Sca1+ cells toward the endothelial fate and studied the effect of cell conversion on vascular 
hyperplasia in a model of endothelial injury. After ETV2 transduction, Sca1+ adventitial cells presented a significant 
increase in the expression of early endothelial cell genes, including VE-cadherin, Flk-1, and Tie2 at the mRNA and 
protein levels. ETV2 overexpression also induced the downregulation of a panel of smooth muscle cell and mesenchymal 
genes through epigenetic regulations, by decreasing the expression of DNA-modifying enzymes ten-eleven translocation 
dioxygenases. Adventitial Sca1+ cells grafted on the adventitial side of wire-injured femoral arteries increased vascular 
wall hyperplasia compared with control arteries with no grafted cells. Arteries seeded with ETV2-transduced cells, on the 
contrary, showed reduced hyperplasia compared with control.
Conclusions—These data give evidence that the genetic manipulation of vascular progenitors is a promising approach to 
improve vascular function after endothelial injury.
Visual Overview—An online visual overview is available for this article.  (Arterioscler Thromb Vasc Biol. 2018;38:232-244. 
DOI: 10.1161/ATVBAHA.117.309853.)
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reendothelization in a murine model of vein graft,7 and similar 
results were observed when VEGF was applied to the adventitial 
side of decellularized vessel grafts.8 These results encouraged us 
to develop a robust and reproducible protocol to direct AdvSca1 
cell differentiation toward EC as a therapeutic approach, and 
thus, preventing the differentiation of vascular progenitor cells 
into SMCs during the development of vascular diseases.
ETV2 (ETS variant 2)—a member of the ETS (E26 trans-
formation-specific) transcription factor family—is a strong 
inducer of EC differentiation during early vascular develop-
ment9 and has been used in several studies, alone or in com-
bination with other factors, to transdifferentiate in vitro mouse 
and human fibroblasts into EC.10,11 In the current study, we 
investigated whether we could direct AdvSca1 cells toward 
the endothelial lineage by overexpressing ETV2 and how the 
cell conversion would affect vascular hyperplasia. Our results 
showed that ETV2 transduction increased EC gene expres-
sion in AdvSca1 cells. ETV2 also downregulated SMC/mes-
enchymal genes expression by decreasing the expression of 
epigenetic modifiers TET (ten-eleven translocation) enzymes. 
AdvSca1 cells transduced with ETV2 in an endothelial injury 
model lost the ability to enhance neointima formation or vascu-
lar remodeling and promoted reendothelization.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
AdvSca1 Cells Are Specified Toward an 
SMC/Mesenchymal Fate In Vitro
To assess the potential of AdvSca1 cells to differentiate into 
EC in vitro without gene manipulation, we cultured the cells 
for 3 days in different conditions: in Dulbecco modified Eagle 
medium with 10% of fetal bovine serum (FBS) and supple-
mented with LIF (leukemia inhibitory factor; to keep the 
undifferentiated state of AdvSca1 cells) or without LIF, with 
and without VEGF; or in Dulbecco modified Eagle medium 
with 10% of serum replacement (SR) with and without VEGF. 
Cells cultured in SR displayed a change of morphology 
(Figure 1A; Figure IA in the online-only Data Supplement) 
with reduced proliferation as shown by measurement of Edu 
incorporation and cell cycle distribution by flow cytom-
etry analysis (Figure IIA and IIB in the online-only Data 
Supplement). AdvSca1 cells cultured in SR (Adv-SR) showed 
an increase in the expression of cd34 expression compared 
with undifferentiated AdvSca1 cells by quantitative real-time 
polymerase chain reaction (RT-PCR). However, endothelial 
gene VE-cadherin (cdh5), cd31, and Flk-1 expression were not 
increased in any culture conditions, and VEGF did not further 
promote EC differentiation in SR medium (Figure IB in the 
online-only Data Supplement). Cd34 is expressed by ECs and 
vascular wall progenitor cells with endothelial potential,12 but 
its expression was also reported on progenitors with smooth 
muscle and mesenchymal potential.13 Consequently, we also 
analyzed the expression of markers specific for other lineages 
and noticed a strong induction of SMC/mesenchymal genes, 
such as αSMA (acta2), Pdgfrβ, cdh11, and col1a, in Adv-SR 
cells (Figure 1C). Immunofluorescence staining confirmed 
the induction of αSMA in Adv-SR cells at the protein level 
(Figure 1B). We concluded that on LIF and serum removal, 
AdvSca1 cells autonomously and preferentially commit to an 
SMC/mesenchymal fate, and VEGF alone is insufficient to 
induce EC differentiation in vitro.
TET and 5hmC Are Upregulated During AdvSca1 
Cell Differentiation Into SMC/Mesenchymal Cells 
In Vitro and in Response to Vascular Injury
We next investigated the potential mechanisms associated 
with the SMC/mesenchymal differentiation of AdvSca1 cells. 
Several studies support the involvement of epigenetic altera-
tions in vascular diseases. Recently, DNA-modifying enzymes 
TET were linked to SMC plasticity and the development of 
atherosclerotic lesions in patients and mice models.14 We 
measured TET (tet1, tet2, and tet3) mRNA levels in AdvSca1 
cells after culture in different conditions (Figure 1D). Because 
TET enzymatic activity is to convert 5-methylcytosine (5mC) 
to 5-hydroxymethylcytosine (5hmC), we also measured 
5hmC levels in genomic DNA from undifferentiated AdvSca1 
cells and differentiated Adv-SR cells (Figure 1E; Figure 
IC in the online-only Data Supplement). Our results dem-
onstrated that elevated TET mRNA and 5hmC levels were 
associated with increased differentiation toward an SMC/
mesenchymal phenotype. We next investigated the effect of 
vascular injury on AdvSca1 cells differentiation using an 
aorta-conditioned medium (CM)-based differentiation assay 
described in a recent study.15 AdvSca1 cells were incubated 
in CM prepared from an ex vivo-injured or uninjured ascend-
ing aorta for 5 days. Immunostaining using a specific anti-
body for αSMA (Figure 1F; Figure ID in the online-only Data 
Supplement) and quantitative RT-PCR for col1a (Figure IE 
Nonstandard Abbreviations and Acronyms
5hmC  5-hydroxymethylcytosine
5mC  5-methylcytosine
Adv-ETV2   adventitial Sca1+ cells differentiated in SR and 
transduced with ETV2 virus
Adv-null   adventitial Sca1+ cells differentiated in SR and 
transduced with null virus
AdvSca1  adventitial Sca1+ progenitor cell
Adv-SR  adventitial Sca1+ cells differentiated in SR
ApoE  apolipoprotein E
CM  conditioned medium
EC  endothelial cell
ETV2  ETS variant 2
IGF1  insulin-like growth factor 1
IGFBP  insulin-like growth factor-binding protein
LIF  leukemia inhibitory factor
RT-PCR  real-time polymerase chain reaction
Sca1  stem cell antigen-1
αSMA, acta2 α-smooth muscle actin
SMC  smooth muscle cell
SR  serum replacement
TET  ten-eleven translocation
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in the online-only Data Supplement) revealed that CM from 
injured aorta stimulated the expression of these SMC/mes-
enchymal genes in AdvSca1 cells at the protein and RNA 
levels, respectively. Quantitative RT-PCR to measure TET 
expression showed a significant increase in Tet3 expres-
sion in AdvSca1 cells incubated with CM from injured aorta 
compared with CM from uninjured aorta (Figure IF in the 
online-only Data Supplement). Immunofluorescence staining 
using a specific antibody for 5hmc also confirmed increased 
DNA hydroxymethylation in AdvSca1 in presence of injured 
aorta-CM compared with uninjured aorta-CM (Figure 1G). 
Altogether, our results showed that AdvSca1 cells differenti-
ate preferentially into SMC/mesenchymal cells in vitro and 
in response to vascular injury conditions. We also showed 
that epigenetic events are associated with SMC/mesenchymal 
differentiation.
ETV2 Directs AdvSca1 Cells Toward an  
Endothelial Fate
To force the differentiation of the cells toward the endothelial 
lineage instead of the SMC/mesenchymal lineage, we trans-
duced AdvSca1 cells with adenoviral particles overexpressing 
Figure 1. Adventitial Sca1+ (AdvSca1) progenitor cells differentiate into smooth muscle cells/mesenchymal cells and undergo epigenetic 
changes in vitro and ex vivo in response to vascular injury. A, Morphology of AdvSca1 cells cultured for 3 d in medium with fetal bovine 
serum (FBS)+LIF (leukemia inhibitory factor) or with serum replacement (SR). B, Immunofluorescence staining of AdvSca1 cells cul-
tured for 5 d in medium with FBS or SR for αSMA (α-smooth muscle actin; red). DAPI (4’,6-diamidino-2-phenylindol) stains nuclei (blue). 
Quantitative real-time polymerase chain reaction of (C) acta2, Pdgfrβ, cdh11, col1a, cd34, and (D) TET (ten-eleven translocation) expres-
sion in AdvSca1 cells cultured in different conditions (experiment done in triplicates; *P<0.05, **P<0.01, ***P<0.001, ****P<0.001; data 
representative of 2 independent experiments). E, Dot blot for global enrichment for 5hmc using genomic DNA (n=3 independent experi-
ments) isolated from AdvSca1 cells cultured in FBS+LIF or SR. Single-strand DNA (ssDNA) antibody shows equal loading. Densitometry 
quantification was performed using ImageJ software. Mouse AdvSca1 cells were cultured for 5 d in presence of conditioned media (CM) 
from uninjured or injured sections of the same rat artery. F, Immunofluorescence staining of AdvSca1 cells for αSMA (red) and increase of 
αSMA+ cells (n=6 arteries; *P<0.05 vs uninjured aorta-CM; 5×20 magnification fields were counted for each experiment). G, Immunofluo-
rescence staining of AdvSca1 cells for 5hmc (green). Intensity of fluorescence per nucleus and per ×40 magnification field, n=4 magnifica-
tion fields, ***P<0.001 vs uninjured aorta-CM. The histogram is representative of results from 4 different arteries.
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ETV2—an EC transcription factor, strong inducer of EC 
differentiation, used in previous studies to transdifferentiate 
fibroblasts into EC.10,11 The cells were placed in SR medium 
with VEGF to facilitate VE-cadherin and cd34 expression. 
After 7 days, the cells were harvested, and ETV2 overexpres-
sion was confirmed by immunostaining (Figure 2A). AdvSca1 
cells overexpressing ETV2 (AdvSca1+ cells differentiated in 
SR and transduced with ETV2 virus [Adv-ETV2]) displayed 
a more endothelial-like morphology compared with undiffer-
entiated AdvSca1 (AdvSca1) and to the cells differentiated 
with the adenovirus control (AdvSca1+ cells differentiated in 
SR and transduced with null virus [Adv-null]; Figure 2B) and 
could take up red fluorescent-labeled acetylated LDL (low-
density lipoprotein; Figure 2C). Global gene expression analy-
sis revealed that Adv-ETV2 cells obtained from 2 independent 
experiments clustered with 2 different EC lines as illustrated 
by hierarchical clustering (Figure 2E) and were enriched for a 
full panel of endothelial-specific genes (Figure 2D). We con-
firmed the strong induction of EC-specific markers, includ-
ing VE-cadherin, flk-1 (VEGFR2), and tie2, and of genes 
involved in angiogenesis and vascular development, such as 
Rasip1 at the mRNA level (Figure 2F and 2G) compared with 
Figure 2. Adenovirus-mediated ETV2 (ETS variant 2) overexpression promotes endothelial differentiation of adventitial Sca1+ (AdvSca1) cells. 
A, Schematic of the differentiation protocol and immunofluorescence staining for ETV2 (red). B, Morphology of AdvSca1, adventitial Sca1+ 
cells differentiated in serum replacement (SR) and transduced with null virus (Adv-null), and adventitial Sca1+ cells differentiated in SR and 
transduced with ETV2 virus (Adv-ETV2) cells at day 7. C, Ability to take up acetylated LDL (low-density lipoprotein; red fluorescence). D, Heat 
map for selected genes shows enriched expression for endothelial cell (EC) genes in Adv-ETV2 cells based on the microarray results. Color 
bar indicates gene expression in scale. E, Hierarchical clustering of global gene expression after microarray. Postnatal mouse smooth muscle 
cell, mouse EC lines CRL2581 (YS-EC) and MS1 (EC) were used as controls. Quantitative real-time polymerase chain reaction of (F) EC recep-
tors cdh5, tie2, Flk-1, and Flt1, transcription factor Fli, and of (G) EC-specific genes Egfl7, Rasip1, and Robo4 in Adv-ETV2, Adv-null cells, and 
AdvSca1 cells cultured in fetal bovine serum (FBS)+LIF (leukemia inhibitory factor) or SR+VEGF (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001; 
n=4 independent experiments). H, Immunofluorescence staining of Adv-null and Adv-ETV2 cells for VEGFR2 (green) and ETV2 (red).
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undifferentiated AdvSca1 cells, AdvSca1+ cells differentiated 
in SR+VEGF, and Adv-null. Flk-1, VE-cadherin, and Rasip1 
induction were confirmed at the protein level (Figures 2H 
and 4D; Figure VA in the online-only Data Supplement). 
Therefore, our results proved that ETV2 alone is sufficient to 
direct the differentiation of AdvSca1 cells toward the endo-
thelial lineage.
Adv-ETV2 Cells Form Capillaries 
In Vivo and Ex Vivo
To compare the potential of AdvSca1, Adv-null and Adv-
ETV2 cells to form capillaries in vivo, the cells were stably 
labeled by infection with histone H2b-RFP (red fluorescent 
protein) lentiviral particles to allow their tracing and used in 
a subcutaneous angiogenesis Matrigel assay. As shown pre-
viously,5 undifferentiated AdvSca1 cells have a limited abil-
ity to spontaneously form capillaries in an in vivo Matrigel 
assay. After ETV2 reprogramming, Adv-ETV2 cells displayed 
increased vasculogenic properties and could be seen incorpo-
rated in a much denser network of vessels (Figure 3A). Similar 
to our in vitro results, Adv-ETV2 RFP cells still expressed 
EC markers VE-cadherin and VEGFR2 in vivo as shown by 
immunofluorescence. The cells also newly expressed EC 
marker cd31, showing that the cells had further differentiated 
(Figure 3A; Figure VI in the online-only Data Supplement). 
The presence of blood cells in the lumen indicating a func-
tional capillary network could only be seen in vessels from 
Matrigel plugs seeded with Adv-ETV2 cells (Figure VI in the 
online-only Data Supplement), confirming that Adv-ETV2 
cells were behaving like functional EC in vivo. Almost no ves-
sel formation occurred within the Matrigel plug with Adv-null 
cells, indicating that the cells do not have the ability to dif-
ferentiate into EC or to promote vasculogenesis (Figure 3A). 
We next investigated whether ETV2 could promote EC dif-
ferentiation of AdvSca1 cells using the ex vivo mouse aortic 
ring assay to study angiogenesis. Aortic ring explants were 
isolated from Sca1-GFP (green fluorescent protein) transgenic 
mice to allow easy detection by fluorescence of the AdvSca1 
cells in the vascular wall. The mice used in this study were 
also from ApoE−/− background because it was described that a 
high number of Sca1+ cells was observed in the adventitia of 
aorta of ApoE null mice.1 The aortic rings cultured in the pres-
ence of ETV2 overexpressing adenovirus for 7 days displayed 
increased sprouting compared with explants cultured with null 
adenovirus (Figure 3B; Figure VIIA in the online-only Data 
Supplement). ETV2 overexpression was confirmed in the tis-
sue and in Sca1+ GFP cells by immunofluorescence staining 
(Figure VIIB in the online-only Data Supplement), and a quan-
tification revealed an increase of GFP cells expressing cd31 
after ETV2 transduction (Figure 3C and 3D). We concluded 
that the overexpression of ETV2 in adventitial progenitor cells 
leads to an increase of cd31+ cells with proangiogenic proper-
ties in the vascular wall.
ETV2 Prevents SMC/Mesenchymal 
Differentiation of AdvSca1 Cells
In accordance with the upregulation of SMC/mesenchymal 
genes in Adv-SR cells (Figure 1C), quantitative RT-PCR 
revealed that several genes of SMC/mesenchymal lineage, 
including acta2, cdh11, pdgfrβ, postn, and profibrotic gene 
col1a, were upregulated in Adv-null and AdvSca1 cells placed 
in SR+VEGF compared with undifferentiated AdvSca1 cells 
kept in FBS+LIF (Figure 4B). The increase in αSMA, pdgfrβ, 
and col1a were also confirmed at the protein level (Figure 4C 
and 4D). Gene ontology analysis of the differentially regulated 
genes between Adv-null and undifferentiated AdvSca1 cells 
according to the microarray data confirmed an upregulation 
of biological processes linked to extracellular matrix organi-
zation and SMC function (Figure III in the online-only Data 
Supplement). Global gene expression analysis and quantita-
tive RT-PCR showed that ETV2 overexpression resulted in 
the inhibition of SMC/mesenchymal gene expression in Adv-
ETV2 cells, including acta2, cdh11, and col1a (Figure 4A and 
4B). Immunostainings and Western blot analysis demonstrated 
that αSMA and col1a expressions were also lower at the pro-
tein level in Adv-ETV2 versus Adv-null cells (Figure 4C and 
4D). Gene ontology analysis confirmed the downregulation 
of genes linked to extracellular matrix organization and con-
trol of the vascular diameter and blood pressure in Adv-ETV2 
compared with Adv-null cells (Figure IV in the online-only 
Data Supplement). Surprisingly, quantitative RT-PCR revealed 
a decrease of cd34 mRNA expression in Adv-ETV2 cells 
(Figure 4B). Cd34 is a marker of EC and endothelial progeni-
tors, and its inhibition could be a barrier for EC differentia-
tion. We performed flow cytometry using an antibody directed 
against cd34 together with an antibody against specific lin-
eage markers Pdgfrβ or Tie2. This allowed us to compare how 
AdvSca1, Adv-null, and Adv-ETV2 cells distributed into the 
mesenchymal and EC lineages and the expression of cd34 in 
the 2 lineages. Our results showed that when removed from 
their maintenance medium, Adv-null cells differentiated into a 
cd34+ Pdgfrβ+ mesenchymal cell type (from 7.9±5.4% SD to 
29±7.5% SD) and that only few of them became cd34+ Tie2+ 
(1.4±0.4% SD) or Tie2+ (1.6±0.5% SD; Figure 4E; Figure 
VB in the online-only Data Supplement). These results are in 
accordance with gene expression analysis (Figures 1C and 4B). 
ETV2 promoted the differentiation of AdvSca1 cells toward the 
EC fate by downregulating the number of cd34+ Pdgfrβ+ cells 
(16.7±6.2% SD) and increasing by 3 folds the ratio of cd34+ 
Tie2+ versus cd34+ Pdgfrβ+ cells (Figure 4E; Figures VB and 
XI in the online-only Data Supplement).
ETV2 Prevents SMC/Mesenchymal Gene 
Expression Through the Downregulation 
of an IGFBP-5-TET Axis
To investigate the involvement of epigenetic events in ETV2-
mediated reprogramming, we compared TET expression pro-
files in AdvSca1 cells cultured in FBS+LIF or SR+VEGF, 
Adv-null, and Adv-ETV2 cells using quantitative RT-PCR. As 
expected, all TETs were upregulated in AdvSca1+ cells differ-
entiated in SR+VEGF and Adv-null compared with AdvSca1 
progenitor cells. We also discovered that tet1 and tet3 mRNA 
levels were significantly lower in Adv-ETV2 cells compared 
with Adv-null, whereas Tet2 levels seemed unchanged after 
ETV2 overexpression (Figure 5A). Tet1 and Tet3 protein lev-
els appeared also lower in the nuclear and perinuclear regions 
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of Adv-ETV2 cells compared with Adv-null cells as shown 
by immunofluorescence staining (Figure 5B; Figure VIII in 
the online-only Data Supplement). We next performed small 
interfering RNA (siRNA)-mediated knockdown of each Tet 
isoform in Adv-SR cells. SiRNA knockdown of Tet1 and Tet2 
led to concomitant downregulation of the other isoforms most 
likely because of redundancy in their sequences. Nevertheless, 
an efficient specific downregulation of Tet3 was achieved, 
with no reduction of Tet1 and Tet2 expression. This allowed 
us to identify the role of Tet3 in the regulation of SMC/
mesenchymal genes expression because Tet3 siRNA transfec-
tion in Adv-SR led to a decrease of αSMA, Pdgfrβ, and col1a 
mRNA levels compared with Adv-SR cells transfected with 
siRNA control (Figure 5C and 5D). Altogether, our results 
imply that the downregulation of Tet3 expression after ETV2 
overexpression is involved in the downregulation of SMC/mes-
enchymal genes observed in Adv-ETV2 cells. Nevertheless, 
further investigation will be needed to determine whether the 
other TETs, and in particular, Tet1, which is also downregu-
lated in Adv-ETV2 cells, play a role in SMC/mesenchymal 
Figure 3. ETV2 (ETS variant 2) overexpression in adventitial Sca1+ (AdvSca1) cells promotes angiogenesis. A, LV H2b-RFP (red fluores-
cent protein) stably transduced AdvSca1, adventitial Sca1+ cells differentiated in serum replacement (SR) and transduced with null virus 
(Adv-null), or adventitial Sca1+ cells differentiated in SR and transduced with ETV2 virus (Adv-ETV2) cells were used for in vivo matri-
gel plug assays. Adv-ETV2 cells formed a denser network of capillary-like structures (black arrows) compared with the 2 other groups 
(*P<0.05; 5 microscope fields were counted for each plug; n=5 plugs for each population). RFP Adv-ETV2 express VE-cadherin (green) 
in newly formed capillaries after immunofluorescence staining. B, Representative bright field pictures and quantification of vascular 
sprouting observed with aortic ring explants from ApoE Sca1-GFP (green fluorescent protein) mice cultured with ETV2 overexpressing 
adenovirus compared with the control null adenovirus (n=18 rings for each group from 3 independent arteries/experiments; *P<0.05). C, 
Quantification of GFP+cd31+ cells (n=5 rings from 2 independent arteries/experiments; *P<0.05). D, Representative pictures of aortic ring 
explants from Sca1-GFP transgenic mice, stained for cd31 (red) after culture with ETV2 overexpressing adenovirus. Arrows indicate cd31-
positive GFP cells.
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differentiation of AdvSca1 cells. The screening of our micro-
array data and quantitative RT-PCR also revealed a strong 
downregulation of Igfbp-5 (insulin-like growth factor-binding 
protein 5) expression in Adv-ETV2 cells (Figures 4A and 5E). 
IGFBP-5 protein is synthetized by vascular smooth muscles 
cells and can be secreted or translocated in the nucleus to act 
as a transcriptional activator.16 IGFBP-5 is strongly induced 
in Adv-SR cells, and its inhibition using specific siRNA in 
Adv-SR cells decreased SMC/mesenchymal genes expres-
sion (Figure 5F and 5G; Figure IXA in the online-only Data 
Supplement). IGFBP-5 KD Adv-SR cells also expressed 
lower levels of TET mRNA, especially tet1 and tet3, indicat-
ing that IGFBP-5 regulates TET expression (Figure 5H). Our 
results demonstrated that IGFBP-5 acts upstream of TET to 
regulate SMC/mesenchymal gene expression and that ETV2 
prevents mesenchymal/SMC differentiation of AdvSca1 cells 
by downregulating the IGFBP-5-TET pathway and excessive 
DNA hydroxymethylation. Interestingly, AdvSca1 cells incu-
bated for 5 days in CM prepared from an ex vivo-injured aorta 
expressed higher levels of nuclear IGFBP-5 compared with 
AdvSca1 cells in CM from uninjured aortas (Figure IXB in 
the online-only Data Supplement).
Figure 4. ETV2 (ETS variant 2) overexpression inhibits the differentiation of adventitial Sca1+ (AdvSca1) cells into smooth muscle cells/
mesenchymal cells. A, Heat map for selected genes shows enriched expression for mesenchymal and profibrotic genes in adventitial 
Sca1+ cells differentiated in serum replacement (SR) and transduced with null virus (Adv-null) cells compared with adventitial Sca1+ cells 
differentiated in SR and transduced with ETV2 virus (Adv-ETV2), from 2 separate experiments based on microarray. Color bar indicates 
gene expression in scale. B, Validation by quantitative real-time polymerase chain reaction of the mRNA changes for the indicated 
genes in Adv-ETV2, Adv-null cells, and AdvSca1 cultured in fetal bovine serum (FBS)+LIF (leukemia inhibitory factor) or SR+VEGF (n=4 
independent experiments; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001). C, Immunofluorescence staining of AdvSca1, Adv-null, and 
Adv-ETV2 cells for αSMA (α-smooth muscle actin) and collagen1. D, Western blot analysis of VE-cadherin, Pdgfrβ, and αSMA expres-
sion in AdvSca1, Adv-null, and Adv-ETV2 cells. GAPDH antibody was used for loading control. Protein extracts from mouse endothelial 
cells MS1 (1) and CRL2581 (2) were used as positive controls for endothelial cell (EC) protein profile expression. E, Quantification by flow 
cytometry of cd34+ Sca1+, cd34+ Pdgfrβ+ and cd34+ Tie2+ populations in undifferentiated AdvSca1, Adv-null, and Adv-ETV2 cells (*P<0.05, 
***P<0.001; n=4–5 independent experiments).
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Adv-ETV2 Cells Improve Vascular Remodeling 
in a Model of Femoral Artery Wire Injury
To study the effect of AdvSca1, Adv-null, and Adv-ETV2 
cells in a context of vascular injury, the cells were stably 
labeled with nuclear H2b-RFP to allow tracing and seeded 
on the adventitial side of wire-injured femoral arteries. One 
week after the injury, RFP cells could be seen in the adven-
titia for all 3 conditions. Arteries transplanted with undif-
ferentiated AdvSca1 cells also displayed RFP cells in the 
neointima, which had already been observed in a previous 
study using the same experimental model with stably GFP-
labeled AdvSca1 cells (Figure 6A).3 The 3 layers of the 
vascular wall of the arteries were measured 2 weeks post-
injury using histological sections and compared with injured 
arteries where no cells were grafted. Similarly to what had 
been described in the work by Yu et al,3 the grafting of a 
high number of exogenous AdvSca1 cells led to an increase 
of the neointima lesion. Adv-null cells stayed localized in 
the adventitia, did not migrate to the neointima, and did not 
increase neointimal hyperplasia but induced a thickening of 
the vascular wall (Figure 6B). We hypothesized that the dif-
ference of localization of the cells in the vascular wall was 
because of differences in migratory properties. We performed 
in vitro transwell assays, which demonstrated that AdvSca1 
cells differentiated into SMC/mesenchymal cells (Adv-SR) 
had reduced basal migration ability compared with undiffer-
entiated AdvSca1 cells (Figure IIC and IID in the online-only 
Data Supplement). Our microarray results and gene ontology 
analysis also confirmed the upregulation of cell adhesion and 
downregulation of cell migration processes in Adv-null cells 
compared with AdvSca1 cells, which are not differentiated 
yet, possibly through changes in their extracellular matrix 
composition, such as higher collagen1a levels, and in the 
expression profile of their integrins and chemokines recep-
tors (data not shown).
Arteries transplanted with Adv-ETV2 showed decreased 
vascular wall remodeling and neointimal hyperplasia com-
pared with all the other groups, including the group of arteries 
with no grafted cells as indicated by reduced adventitia/media 
and intima/media ratios (Figure 6B and 6C). One component 
Figure 5. Identification of an IGFBP (insulin-like growth factor-binding protein)-5–TET (ten-eleven translocation) pathway involved in the 
differentiation of the adventitial Sca1+ (AdvSca1) cells into smooth muscle cells (SMCs)/mesenchymal cells. A, Quantitative real-time 
polymerase chain reaction (RT-PCR) of tet1, tet2, and tet3 mRNA expression in AdvSca1 cells cultured in fetal bovine serum (FBS)+LIF 
(leukemia inhibitory factor), serum replacement (SR)+VEGF, adventitial Sca1+ cells differentiated in SR and transduced with null virus 
(Adv-null), and adventitial Sca1+ cells differentiated in SR and transduced with ETV2 (ETS variant 2) virus (Adv-ETV2) cells (n=3 indepen-
dent experiments; *P<0.05, **P<0.01). B, Immunofluorescence staining of AdvSca1, Adv-null, and Adv-ETV2 cells for TET3 (red). DAPI 
(4’,6-diamidino-2-phenylindol) stains nuclei (blue). Quantitative RT-PCR of (C) tet and (D) SMC genes acta2, pdgfrβ, and col1a expression 
in AdvSca1 cells after 3 d in FBS or SR with transfection of ctrl siRNA or siRNA against tet1, tet2, and tet3 (triplicate; *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001; data representative of 2 independent experiments). E, IGFBP-5 mRNA expression in Adv-null and Adv-ETV2 
cells. Quantitative RT-PCR of (F) IGFBP-5, (G) SMC genes acta2, pdgfrβ, cdh11, and col1a, and (H) TET gene expression in AdvSca1 
cells after 3 d in FBS or SR with transfection of ctrl siRNA or siRNA IGFBP-5 (triplicate; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001; data 
representative of 2 independent experiments).
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of vascular hyperplasia is cell proliferation. After injury, 
cells in the media and at the external border of the media, 
negatives for Sca1 expression showed increased proliferation 
(Figure XA and XB in the online-only Data Supplement), 
and this effect was amplified with the grafting of Adv-null 
cells but not Adv-ETV2 as seen by PCNA (proliferating cell 
nuclear antigen) immunostaining followed by quantifica-
tion (Figure 7A). After 2 weeks, few RFP cells could still be 
detected (data not shown), so we hypothesized that the effect 
of the progenitors on hyperplasia could be explained by para-
crine effects on SMC proliferation. We performed coculture 
experiments where SMCs were plated in a transwell on top 
Figure 6. Adventitial Sca1+ cells differentiated in serum replacement (SR) and transduced with ETV2 (ETS variant 2) virus (Adv-ETV2) 
cells improve vascular remodeling in a model of arterial injury. A, LV H2b-RFP (red fluorescent protein) stably transduced adventi-
tial Sca1+ (AdvSca1), adventitial Sca1+ cells differentiated in SR and transduced with null virus (Adv-null), and Adv-ETV2 cells were 
seeded on the adventitial side of a wire-injured femoral artery. One week after the injury, RFP cells could be seen in the adventitia of 
all groups. RFP cells could also be seen in the neointima of arteries where AdvSca1 cells were transplanted. (A, adventitia; N, Neo-
intima). B, Representative image of Hematoxylin and Eosin (top) and elastin (bottom) staining performed on histological sections, 
2 wk post-injury for each group: arteries with no cells, seeded with AdvSca1 cells, Adv-null, or Adv-ETV2 cells. Arrows indicate the 
external limit of the intima, media, and adventitia. C, Measurements of the adventitia, media, and neointima and calculation of the 
intima/media and adventitia/media ratios were made on 3 sections per injured artery (n=6 arteries for each group; *P<0.05, **P<0.01). 
Measurements of adventitia, media, and adventitia/media ratio for uninjured arteries are also indicated (3 sections were analyzed per 
artery; n=4 arteries).
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of Sca1+ adventitial cells. After Edu incorporation, SMC were 
harvested, fixed, and analyzed for cell cycle distribution. Our 
results showed that adding undifferentiated AdvSca1 cells to 
the culture could decrease SMC proliferation but that after 
SMC/mesenchymal differentiation, the cells (Adv-SR) had 
lost their antiproliferative effect (Figure XC in the online-
only Data Supplement). Similarly, SMC cultured with Adv-
null cells showed more proliferation than when cultured with 
undifferentiated AdvSca1 cells. Overexpressing ETV2 in the 
adventitial progenitors partially rescued the antiproliferative 
effect on SMC (Figure 7B). Immunostaining using cd31 anti-
body showed that 1 week post-injury, reendothelization was 
improved in arteries grafted with Adv-ETV2 (Figure 7C). 
We only detected occasionally RFP Adv-ETV2 cells in the 
endothelial layer of the arteries 1 week post-injury indicating 
that Adv-ETV2 indirectly contributed to the reendothelization 
process. Therefore, the positive effect of Adv-ETV2 cells on 
vascular remodeling could be explained by a combination of 
antiproliferative and proangiogenic properties.
Discussion
In accordance to previous findings, we observed that 
AdvSca1 cells grafted on the adventitial side of a wire-
injured femoral artery migrated within the vascular wall 
toward the luminal side of the vessel and increased neointi-
mal hyperplasia.3 We also showed that the overexpression 
of ETV2 in AdvSca1 cells was sufficient to direct the cells 
toward the endothelial lineage while preventing them from 
acquiring an αSMA+ phenotype with pathological proper-
ties. This work presents the first evidence that the transdif-
ferentiation of AdvSca1 cells into ECs, that is, controlling 
the cell fate of vascular wall resident progenitor cells by 
gene transfer, is a promising therapeutic approach against 
vascular diseases.
Twenty percent of the AdvSca1 cells used in this study 
expressed cd34 marker, 20% expressed Pdgfrβ, and <1% 
expressed Tie2. Majesky et al5 have recently described the 
heterogeneity within AdvSca1 cells. Using in vivo fate map-
ping, they showed that the AdvSca1 pool is composed of 2 
Figure 7. Adventitial Sca1+ cells differentiated in serum replacement (SR) and transduced with ETV2 (ETS variant 2) virus (Adv-ETV2) cells 
induce less smooth muscle cell (SMC) proliferation in vitro and in vivo and facilitate reendothelization of injured arteries. A, Representative 
picture of immunohistochemistry using PCNA (proliferating cell nuclear antigen) antibody performed on sections of 2 wk postinjury arter-
ies where no cells, adventitial Sca1+ cells differentiated in SR and transduced with null virus (Adv-null), or Adv-ETV2 cells were seeded 
(n=4 arteries). Arrows indicate the external limit of the intima and media. PCNA+ cells of the media were quantified for each experimental 
group (**P<0.01; n=4). B, SMCs were cultured on transwells on top of undifferentiated adventitial Sca1+, Adv-null, or Adv-ETV2 cells for 
3 d. SMCs were incubated with Edu for 2 h, harvested, fixed, and analyzed for cell cycle distribution using Fx cycle (*P<0.05, **P<0.01 
***P<0.001; n=3; data representative of 2 independent experiments). C, Immunostaining using cd31 antibody of paraffin section of 1-wk 
postinjury arteries where no cells, Adv-null, or Adv-ETV2 cells were seeded.
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separate populations. One population originated from differ-
entiated SMC (SMC-derived AdvSca1 cells) and contributed 
to adventitial remodeling after injury. Several subpopula-
tions were identified within SMC-derived AdvSca1 cells 
depending on the expression of markers, such as Pdgfrβ. The 
AdvSca1 cells used in our study share several similarities 
with SMC-derived AdvSca1 cells, including common mark-
ers and a predisposition to differentiate into SMC and mural 
cells rather than ECs. When AdvSca1 cells were placed in 
culture without LIF and with SR for 5 days to promote their 
differentiation, a strong increase in the number of Sca1+ 
cd34+ cells could be measured. Cd34 has been found to be 
expressed on the surface of mesenchymal,13,17 SMC,1 and EC 
progenitors12 and could be identifying cells that have left the 
multipotent progenitor state Sca1+ to a more lineage com-
mitted one Sca1+ cd34+. These observations are based on in 
vitro experiments. Therefore, after successfully generating 
a Sca1 knock-in inducible Cre mice, our next step is to con-
firm in vivo that Sca1+ cd34+ cells originate from Sca1+ cells. 
A recent study showed that adventitial Gli1+ cd34+ Pdgfrβ+ 
cells could migrate to the neointima of injured arteries and 
differentiate into SMC-like cells expressing αSMA and 
calponin.4 cd34+ Tie2+ VEGFR2+ VE-cadherin+ cd31− cells 
located in the vasculogenic zone between the adventitia and 
the media of human thoracic arteries, on the opposite, were 
identified as endothelial precursors able to form sprouts ex 
vivo.12 Our results implicate that ETV2 overexpression pro-
motes in vitro the commitment of AdvSca1 cells toward an 
endothelial progenitor fate by inhibiting the differentiation 
into cd34+ Pdgfrβ+ cells while promoting the emergence 
of cd34+ Tie2+ cells (Figure XI in the online-only Data 
Supplement).
Both AdvSca1 (data not shown) and Adv-null cells 
increased cell proliferation within the vascular wall in vivo 
but in different layers because of different localization. Based 
on our in vitro coculture proliferation assays and ex vivo 
CM differentiation assays, we postulate that in the context of 
vascular injury, AdvSca1 cells differentiate toward a mesen-
chymal fate promoting SMC proliferation through paracrine 
effect, leading to enhanced vascular hyperplasia. PDGF-DD 
could mediate this effect because our microarray indicated it 
is expressed in Adv-null cells. It was shown that PDGF-DD is 
overexpressed in ApoE-deficient mice and can induce KLF4 
(Kruppel-like factor 4) expression and phenotypic modula-
tion in SMC.18 ETV2 overexpression decreased Pdgfd gene 
expression and reduced the proliferative effect on SMC.
ETV2 is a critical transcriptional activator of EC gene 
expression during vascular development.9 ChIP-seq analy-
sis indicated that ETV2 directly binds to promoters and 
enhancers of endothelial genes, including Flk-1, Fli1, Tie2, 
VE-cadherin, Dll4, and Nrp2.19 Several studies also dem-
onstrated that ETV2 is important for the specification of 
the mesoderm: in the absence of ETV2, endothelial and 
endocardial progenitors differentiate into cardiomyocytes.20 
Mechanistically, one report showed that miR-130a—a direct 
target of ETV2—promoted the endothelial program at the 
expense of the cardiac program by blocking Pdgfrα expression 
and signaling.21 In a recent study, ETV2 overexpression alone 
was sufficient to convert human adult fibroblasts into EC. In 
accordance with our findings, a downregulation of fibrotic 
genes, such as col1a2, could be observed together with the 
increase of EC genes expression in the reprogrammed cells.11 
The authors also suggested that ETV2 functions through 
the recruitment of cofactors, such as FoxC2 (Forkhead box 
C2), and of epigenetic modifiers but did not specifically 
investigate the mechanisms by which ETV2 downregulated 
the fibroblastic signature. In this report, we showed that 
ETV2 can repress SMC/mesenchymal gene expression by 
decreasing DNA hydroxymethylation in the AdvSca1 cells 
through the downregulation of an IGFBP-5-TET axis. DNA 
hydroxymethylation has been linked to SMC plasticity and 
vascular remodeling. A recent study has reported the loss of 
Tet2 expression and a reduction of 5hmc marks in SMC in 
response to injury and in coronary atherosclerotic plaques.14 
Reduced Tet2 expression leads to reduced 5hmc, increased 
5mc, reduction of SMC differentiation marker genes, and 
increased vascular remodeling.22 Our results showed that in 
AdvSca1 cells, the increase of tet3 expression and of 5hmc 
enrichment promotes SMC/mesenchymal gene expression 
and that ETV2 counteracts this effect by inhibiting IGFBP-5 
expression. IGFBP-5 is known to be expressed and secreted 
by SMC and to modulate extracellular IGF1 (insulin-like 
growth factor 1) availability and effect on SMC proliferation 
and migration.23 It was also shown that IGFBP-5 can trans-
locate to the nucleus of porcine SMC, contains a transacti-
vation domain, and functions as a transcriptional activator 
independently of IGF signaling.16 We identified here a new 
role for IGFPP-5 in the transcriptional regulation of AdvSca1 
gene expression. Interestingly, IGFBP-5 mRNA expression is 
increased in atherosclerotic pig aortas compared with normal 
arteries24 and is also overexpressed in lung fibrosis where it 
was shown to induce the transcription of collagen and fibro-
nectin.25 Our results showed that AdvSca1 cells incubated in 
CM prepared from an ex vivo-injured aorta expressed higher 
levels of nuclear IGFBP-5 compared with AdvSca1 cells 
in CM from uninjured aortas. Further investigation will be 
needed to establish whether IGFBP-5 could serve as marker 
of atherosclerosis.
Our work could have potential future clinical implications. 
After vascular injury, excessive vascular wall remodeling, 
including activation of the adventitia and intimal hyperpla-
sia, can lead to restenosis. In this report, we confirmed that 
AdvSca1 cells can enhance vascular remodeling, and we 
showed that their transdifferentiation into EC using single-
gene delivery of ETV2 can prevent this pathological effect. 
The transplantation of Adv-ETV2 cells on wire-injured femo-
ral arteries even improved the remodeling compared with con-
trol arteries where no cells were grafted, by preventing SMC 
proliferation and promoting reendothelization.
Previous studies have shown that an increase in adventi-
tial angiogenesis could have negative consequences on plaque 
growth and stability.26 For instance, the adenoviral delivery of 
proangiogenic factors, such as VEGF-A and VEGF-D, led to 
a significant increase in the intima/media ratio and a signifi-
cant positive correlation was observed between the size of the 
adventitial vasa vasorum network and intimal hyperplasia,27 
whereas antiangiogenic molecules, such as endostatin, have 
been shown to reduce intimal neovascularization and plaque 
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growth in ApoE null mice.28 Consequently, the short- and 
long-term effects of a gene therapy involving cell fate modi-
fication of vascular progenitor cell to promote their EC com-
mitment and prevent their SMC/mesenchymal differentiation 
still need to be investigated to evaluate the positive and nega-
tive implications this strategy could have on the progression 
of vascular diseases.
We established a protocol based on the adenovirus-
mediated single-gene delivery of ETV2. As revealed by the 
variations in the gene changes between duplicate samples 
submitted for microarray analysis, the efficiency of ETV2 
transduction varies, and differences in the level of remain-
ing cells nontranduced in the Adv-ETV2 groups might cre-
ate individual EC and SMC/mesenchymal gene variations 
(Figures 2D, 2E, and 4A). A positive selection of the trans-
duced cells would allow the generation of a more homogenous 
EC-like population. The focus of our study was, however, not 
to generate a pure endothelial population but to prove that the 
single-gene delivery of ETV2 was sufficient to promote the 
differentiation of AdvSca1 cells toward the endothelial fate, 
which could have translational applications for in vivo repro-
gramming and gene therapy.
We think our results are encouraging for the develop-
ment of future cell and gene therapies approaches targeting 
AdvSca1 cells to improve vascular remodeling after angio-
plasty or stenting. The localization of AdvSca1 cells on the 
outer layer of the vessel also make them interesting candidates 
for gene manipulation strategies or in vivo reprogramming. 
Our findings may open new therapeutic perspectives for other 
vascular diseases, including hypertension, or for pathologies 
linked to fibrosis because it was shown that Sca1+ matrix-pro-
ducing cells contribute to aortic fibrosis.29
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Highlights
• Adventitial Sca1+ (stem cell antigen-1) progenitor cells are specified toward smooth muscle cell/mesenchymal fate.
• The transduction of endothelial-specific transcription factor ETV2 (ETS variant 2) can direct the differentiation of adventitial Sca1+ cells toward 
the endothelial lineage.
• ETV2 decreases the expression of smooth muscle cell/mesenchymal gene expression by downregulating IGFBP (insulin-like growth factor-
binding protein)-5 and TET (ten-eleven translocation) expression.
• Sca1+ cells transduced with ETV2 improve vascular remodeling when seeded on wire-injured femoral arteries.
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Figure I. AdvSca1 cells differentiate into SMC/mesenchymal cells and undergo epigenetic changes
in vitro and ex vivo in response to vascular injury. A, Morphology of AdvSca1 cells cultured for 3
days in stem cell medium supplemented with FBS+LIF, FBS, FBS+VEGF, or differentiation medium
SR, or SR+VEGF. No typical EC cobblestone morphology was observed in any conditions. B,
Quantitative RT PCR analysis of EC genes expression in AdvSca1 cells cultured in different
conditions (experiment performed in triplicate,*p<0.05,**p<0.01, data representative of 2
independent experiments). C, Immunofluorescence staining of AdvSca1 cells cultured in FBS or SR
for αSMA (red) or 5hmc (green) showed the correlation between increased DNA hydroxymethylation
and SMC/mesenchymal differentiation. Mouse AdvSca1 cells were cultured for 5 days in presence of
conditioned media (CM) from uninjured or injured sections of the same rat artery D, Higher
magnification of immunofluorescence staining for αSMA (red) of AdvSca1 cells treated with injured
aorta CM shows the stress fiber organization. Quantitative RT PCR shows increase in (E) col1a
expression and (F) Tet3 expression (n=9 arteries, *p<0.05 versus non injured aorta-CM).
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Figure II. AdvSca1 cells cultured in different conditions show changes in their proliferation and migration
properties. A, Representative pictures of flow cytometry analysis for Edu and cell cycle distribution of
AdvSca1 cells cultured for 3 days in FBS+LIF, FBS, SR and SR+VEGF. B, Percentage of AdvSca1 cells
in S-phase for the different groups (***p<0.001, n=3, data representative of 2 independent experiments).
AdvSca1 cells were cultured for 5 days in FBS+LIF or SR and then assessed for migration ability by
transwell assay C, x10 magnification images of the transwell inserts of the overnight migrated AdvSca1.
D, Quantification of transwell migration assay after 6h and overnight. 5 fields at x10 magnification of
each insert for each condition were considered for quantification of cell migration (*p<0.05 , ***p<0.001
n=3).
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Figure III: Gene ontology analysis of the differentially regulated genes between Adv_NULL and
Adv_Sca1. Gene ontology analysis was performed on the upregulated and downregulated genes of
Adv_NULL compared to Adv_Sca1. Enrichment in gene ontology of biological processes are revealed.
Significance of enrichment was evaluated by p-value.
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Figure IV. Gene ontology analysis of the differentially regulated genes between Adv_ETV2 and
Adv_NULL. Gene ontology analysis was performed on the upregulated and downregulated genes of
Adv_ETV2 compared to Adv_NULL. Enrichment in gene ontology of biological processes are revealed.
Significance of enrichment was evaluated by p-value.
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Figure V. Phenotypic characterization of AdvSca1, Adv_NULL and Adv_ETV2 cells.
A, Immunofluorescence staining of AdvSca1, Adv_NULL and Adv_ETV2 cells for
Rasip1 (red) and beta-catenin (green). B, Quantification of the percentage of Sca1+
cells, Tie2+ cells and measurement of the cd34+Tie2+/cd 4+Pdgfrβ+ ratio in
AdvSca1, Adv_NULL and Adv_ETV2 cells (*p<0.05, n=4-5 independent experiments).
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Figure VI. Adv_ETV2 cells express EC markers in vivo and form functional vascular
networks in a subcutaneous matrigel plug assay. (Top) Immunofluorescence staining for
cd31, VEGFR2, and VE-cadherin, of matrigel plugs sections where Adv_ETV2 cells stably
expressing nuclear RFP were seeded. (Bottom) Sections of matrigel plugs seeded with
Adv_ETV2 cells and stained for Hematoxylin and eosin staining showed the presence of
blood cells in the newly formed vessels.
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Figure VII. Ex vivo adenoviral delivery of ETV2 in Sca1+ cells of aortic ring explants
increases vascular sprouting. Aortic rings from Sca1-GFP mice were cultured for 7 days in
presence of control NULL or ETV2 overexpressing adenovirus. A. Higher magnification
pictures of the aortic rings explants allows the visualization of the vascular sprouts. B, Both
groups of rings were stained by immunofluorescence for ETV2 (red). GFP+ cells (Sca1+)
(white arrows) can be seen expressing ETV2 in the rings treated with ETV2 adenovirus and
included in the vascular sprouts.
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Figure VIII. Tet methylcytosine dioxygenases are differentially expressed in AdvSca1 cultured in FBS+LIF
(AdvSca1) or SR+VEGF (Adv_SR+VEGF), Adv_NULL and Adv_ETV2 cells. Immunofluorescence staining for
TET1 and TET3 (red). DAPI stains nuclei blue and quantification of intensity of fluorescence per nucleus and per
x40 magnification field, n=3 magnification fields (*p < 0.05, **p < 0.01, ***p < 0.001)
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Figure IX. IGFBP-5 is involved in SMC differentiation of AdvSca1 cells. A, Quantitative RT PCR
analysis of IGFBP-5 expression in AdvSca1 cells after culture in different conditions (Experiment
performed in triplicate, ***p<0.001, ****p<0.0001, data representative of 2 independent experiments).
B, Immunofluorescence staining for IGFBP-5 (red), of AdvSca1 cells cultured for 5 days in CM from
uninjured or injured rat artery. Intensity of fluorescence per nucleus and per x40 magnification field,
n=5 magnification fields, ***p < 0.001 versus uninjured aorta-CM. The histogram is representative of
results obtained from 3 different arteries.
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Figure X. AdvSca1 cells modulate SMC proliferation. A, Immunohistochemistry using PCNA antibody
on sections from uninjured and 2 weeks post injury femoral arteries. B, Immunofluorescence staining
using Sca1 (in red) and ki67 (in white) antibodies on sections from uninjured and 1 week post-injury
femoral arteries. White arrows indicate ki67+ cells in the media and at the border media/ adventitia. The
yellow arrow in the inset indicates Sca1+ cells. The internal elastic lamina can be seen by
autofluorescence (green channel). C, SMC were cultured for 48 hours alone or in co-culture with
undifferentiated AdvSca1 or cells differentiated in SR for 3 days (Adv_SR). SMC were analyzed for Edu
and cell cycle distribution by flow cytometry (***p<0.001, n=3, data representative of 2 independent
experiments).
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Figure XI. Schematic of AdvSca1 cells differentiation and ETV2 reprogramming model. When placed
in differentiation conditions, AdvSca1 cells escape a multipotent progenitor state for a Sca1+ cd34+
bipotent progenitor state through DNA hydroxymethylation. ETV2 overexpression decreases the
expression of tet3, preventing further DNA hydroxymethylation of SMC/mesenchymal genes and reducing
their expression, therefore forcing the differentiation AdvSca1 cells towards the endothelial fate.
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MATERIAL AND METHODS 
 
Mouse adventitial progenitor cells isolation, sorting and culture. Mouse vascular 
progenitor cells were derived from the outgrowth of adventitial tissues as previously described1 
. AdvSca1 cells were selected with anti-Sca1 immunomagnetic microbeads (Miltenyi Biotec, 
GmbH, Bergisch Gladbach, Germany), sorted with a magnetic cell separator and cultured in 
stem cell culture medium composed of Dulbecco’s Modified Eagle's Medium (DMEM) (ATCC, 
Rockville, Massachusetts, USA) with 10% ES Cell Qualified Fetal Bovine Serum (FBS) 
(Embryomax, Millipore), 10 ng/ml leukemia inhibitory factor (Merck Millipore LIF1050), 0.1 mM 
β-mercaptoethanol (GIBCO), 100U/ml penicillin/streptomycin (GIBCO) and 2mM L-glutamine 
(GIBCO). AdvSca1 cells were passaged every 3 days at a ratio of 1:3 on gelatin coated flasks. 
Cells were sorted for Sca1+ marker every 5 passages.  
 
Transdifferentiation of AdvSca1 cells towards the endothelial lineage. AdvSca1 cells 
were plated in stem cell media without LIF. At day 2, the medium was replaced with a 
differentiation medium composed of KO DMEM (ThermoFisher) supplemented with 10% KO 
serum replacement (Life technologies) 0.1mM β-mercapto-ethanol, 100U/ml 
penicillin/streptomycin, 2mM L-glutamine and 25 ng/mL of recombinant murine VEGF165 
(Peprotech). Adenovirus overexpressing mouse cDNA for ETV2 and adenovirus control 
(NULL) were purchased from ABM. Titer was evaluated using QuickTiter Adenovirus Titer 
ELISA Kit (Cambridge biosciences LTD). AdvSca1 cells were infected with a MOI of 100.  
Differentiation medium and VEGF were replaced at day 4 and 6. The cells were harvested at 
day 7. 
 
Rat artery conditioned medium (CM). Ascending portions of rat aortas were isolated, flat 
opened and cut in two equal pieces. One part was used to injure ex vivo the endothelial layer 
using a cotton bud and the other one was left uninjured as described by Li et al2. Aorta 
fragments were then placed in 600 µl of ATCC DMEM at 37°C with antibiotics. Conditioned 
medium was collected after 48 h. 300 µL of DMEM medium (10% embryomax, without LIF) 
was then added with 300 µL of conditioned media from uninjured and injured aorta on 5000 
AdvSca1 cells plated the day before. The media was replaced (300 µL DMEM+10% 
Embryomax+300 CM) after 3 days. Cells were fixed or harvested at day 5 for 
immunofluorescence or quantitative RT PCR analysis.  
 
Microarray analysis. Mouse genome-wide expression analysis were performed using 
Affymetrix GeneChip Mouse Gene 2.0 ST Arrays. Total RNA from three lines of mouse 
AdvSca1, Adv_NULL, SMC, and 2 lines of Adv_ETV2 and EC (MS1 cells, ATCC CRL-2279) 
as well as one additional mouse EC line (yolk sak EC, ATCC, CRL-2581) were extracted using 
QIAGEN RNeasy Mini kit. Data were analyzed using Affymetrix expression console and 
transcriptome analysis console 3.0. Hierarchical clustering of global gene expression following 
microarray analysis was performed using a filter of -3.5/+3.5 for the differentially expressed 
genes between Adv_NULL and Adv_ETV2 groups. Gene ontology (GO) enrichment analysis 
was also performed using online software (geneontology.org) to compare upregulated and 
downregulated biological processes between respectively Adv_NULL/Adv_Sca1 cells and 
Adv_ETV2/Adv_NULL cells. Genes upregulated or downregulated more than 2 folds between 
the 2 groups according to the microarray data were used for the analysis.  
AdvSca1 progenitor cells /SMCs co-culture and SMC proliferation assay. 30 000 SMCs 
were plated on cell culture inserts (Sls lifesciences, 3531102) in DMEM, 10% FBS on top of 
progenitor cells plated the day before in 6 wells plates (105 cells/well). 48 to 72 h later, SMC 
were incubated with Edu (10µM) for 2h, harvested, fixed and permeabilized. Edu was then 
detected using Click-it Plus Edu Flow Cytometry Assay kit (molecular probes, C10632), DNA 
content was stained using Fx cycle Far red Stain (Invitrogen, F10348). Cells were then 
analyzed by flow cytometry and the results were analyzed using FlowJo software. Results 
presented are representative of two independent experiments performed in triplicates. 
 
Transwell migration assay. On the lower chamber of transwell inserts with 8.0 μm pore size 
membrane filters, 800 μL of 0.2% FBS, ATCC medium was added. Next, 5x104 cells of 
AdvSca1 cells previously cultured for 5 days in FBS+LIF or SR were resuspended in 200 μL 
of  medium and were loaded into the upper chamber of the transwell insert. After 6 hours or 
overnight incubation, non-migrating cells on the upper chamber side of the filters were 
carefully washed with PBS and removed using a cotton bud. The migrated cells on the lower 
side of the membrane were fixed with 4% PFA in PBS for 10 minutes at room temperature 
and then stained with 0.1% crystal violet dye for at 15 minutes at room temperature. After a 
final washing step, the inserts were dried the migrated cells were counted in 5 different fields 
of each insert at 10X magnification. Data was expressed as the fold of migrated AdvSca1_SR 
compared to AdvSca1 progenitors in FBS+LIF (n=3, Student’s T test was used for statistical 
analysis) 
 
RFP labelling of the cells. Lentiviral particles were generated by transfecting HEK293T cells 
with LV H2b_RFP plasmid (addgene. #26001) and used to stably label the nucleus of 
adventitial cells. Efficiency of the infection was assessed by fluorescence microscopy. One 
flask of 175 cm2 infected AdvSca1 RFP cells was passaged in 3, to keep AdvSca1 cells for 7 
days or generate Adv_NULL and Adv_ETV2 cells. Consequently, cells from same batch, same 
passage, and same level of infection were used for the in vivo experiments (Matrigel plug 
assay and femoral artery wire injury).  
 
Mice. All procedures were performed according to protocols approved by the Institutional 
Committee for Use and Care of Laboratory Animals. C57BL/6J mice were purchased from 
Harlan, UK. Sca_GFP transgenic mice were purchased from The Jackson Laboratory (Bar 
Harbour, Maine, USA). 
 
Aortic ring angiogenesis assay. Aortic rings were isolated from ApoE Sca1-GFP transgenic 
mice, placed in Matrigel, and cultured in OptiMEM (ThermoFisher) supplemented with 
25ng/mL of recombinant mouse VEGF (Peprotech) for 7 days in the presence of control NULL 
or ETV2 overexpressing adenovirus. Medium and adenoviral particles were replaced every 2 
days. The aortic rings were then fixed and processed for immunofluorescence analysis, using 
antibodies against cd31 (abcam, ab28364, 1/50) or ETV2 (Santa cruz, sc-164278, 1/50). 
 
Femoral artery wire injury. Mice were anesthetized with ketamine and medetomidine 
hydrochloride and the surgical procedure was performed as previously described3. Femoral 
arteries were injured by insertion of a guide wire (CROSS-IT 100XT, HI-TORQUE). The 
adventitial side of the arteries were seeded with stably labelled H2b_RFP AdvSca1, 
Adv_NULL and Adv_ETV2 cells (1x106 cells) within 25 μl Matrigel® Basement Membrane 
Matrix (Corning). An injured artery with no seeded cells served as a control. Arteries were 
harvested 7 or 14 days following the injury and used to prepare frozen (for 
immunofluorescence) or paraffin sections (for Hematoxylin and Eosin, Elastica Van Giesen 
and immunohistochemistry). Measurements of the adventitia, media and neointima and 
calculation of the intima/media and adventitia/ media ratios were made on 3 hematoxylin and 
eosin stained sections per injured artery (n=6 arteries for each group).  
 
In vivo Matrigel Plug Assay. 106 stably H2b_RFP labelled AdvSca1 Adv_NULL or 
Adv_ETV2 were mixed with 50 μl of PBS and 250 μl Matrigel. The cell mixture was injected 
subcutaneously into the mice. Five injections were conducted for each group. The plugs were 
harvested 7 days later. Samples were fixed in liquid nitrogen, cryosections were prepared and 
immunofluorescence staining was then performed. 
 
RT-PCR. Total RNA was isolated using a QIAGEN RNeasy Mini kit according to the 
manufacturer’s instructions. 400ng to 1µg of RNA were reverse transcribed into cDNA with 
random primers using the MMLV reverse transcriptase kit (Promega). 
 
Quantitative Real Time Polymerase Chain Reaction. Real time PCR was performed in 
technical duplicates using 20 ng of cDNA per sample with a SYBR Green Master Mix in a 20 
μl reaction. Ct values were measured using the Eppendorf Mastercycler ep Realplex and 
GAPDH was used as an endogenous control to normalize the amounts of RNA in each 
sample. A list of the primers used for PCR amplification is provided at the end of this section.  
 
Western Blot. Cells were lysed with lysis buffer in the presence of protease inhibitors (Santa 
Cruz), and protein concentrations were measured using the Bradford method.15 μg of protein 
lysate were applied to 4-12% Bis-Tris Protein gels (NuPAPE, Novex) before being transferred 
to a nitrocellulose membrane (Amersham Biosciences), followed by a standard western 
blotting procedure. The membrane was incubated with primary antibodies overnight at the 
following dilutions: VE-cadherin (abcam, ab33168, 1/300), αSMA (sigma, A5228, 1/1000), 
PDGFRβ (abcam, ab32570 1/2500), GAPDH (santa cruz, sc25778, 1/200). The next day, the 
membrane was incubated with appropriate secondary antibody at 1/10000 dilution (Dako) for 
2 hours at room temperature before revelation.  
 
Flow cytometry. Cells were harvested, fixed with 2% PFA for 20 min, washed with PBS and 
incubated with conjugated antibody for 30 mins on ice before flow cytometry. Compensation 
was performed and data was analyzed using FlowJo software. Conjugated antibodies list: anti-
mouse Ly6A/E (Sca1) PerCP-Cyanine 5.5 PercP (eBiosciences, 45-5981), anti-mouse cd34 
FITC (BD Pharmingen 553733), anti-mouse CD202b (Tie2) PE (eBiosciences, 12-5987), anti-
mouse CD140b (PDGFRβ) PE (eBiosciences, 12-1402). 
 
TET1/2/3 and IGFBP-5 gene knockdown.  Tet1 (D-062861-01), Tet2 (D-058965-02), Tet3 
(D-054156-01), IGFBP-5 (D-054834-01, D054834-02) siRNA and Non-Targeting siRNA 
control (D-001210-01-05) were purchased from Dharmacon (siGENOME). 60000 cells were 
plated on 6 well plates the day before. The next day, medium was replaced with DMEM with 
FBS or SR and siRNA was performed using Lipofectamine RNAiMAX transfection reagent 
(ThermoFisher) and following the manufacturer’s instructions. Two siRNA targeting different 
sequences of the TET and IGFBP-5 genes were transfected. 72h after transfection, the level 
of down regulation was assessed using real time qPCR and the results for the most efficient 
siRNA (TET) or both siRNA (IGFBP-5) are represented. Experiments were performed in 
triplicates and are representative of 2 independent experiments.  
 
Dot Blot. Genomic DNA was extracted using Wizard Genomic DNA purification kit (Promega) 
following manufacturer’s instruction. For Dot Blot, genomic DNA of Adv_Sca1 cultured in 
FBS+LIF or SR for 5 days (3 independent experiments) was denaturated for 10 min at 95℃ 
and 200 ng were placed on a nitrocellulose membrane (Amersham Biosciences) which was 
air dried and UV crosslinked for 15 min. The membrane was then blocked with 5% milk in 
TBST for 1h, and incubated overnight 4°C with 5hmc antibody (diagenode, pAb-HMC-050, 
rabbit polyclonal, 1/2500). Another membrane was blotted using a single stranded DNA 
antibody to control equal DNA amount (Millipore, MAB 3034 1/2500). The membrane was then 
incubated 1h with the secondary antibody (Dako, 1/10000) at room temperature before 
revelation. Quantification of 5hmc and ssDNA signals was performed using Image G software.   
 
Acetylated low density lipoprotein (ac-LDL) uptake assay. Cells were incubated with 
10μg/ml Alexa Fluor 594 conjugated Ac-LDL (ThermoFisher, L-35353) for 4 hours, stained 
with DAPI and pictures were taken under fluorescence microscope. Images are representative 
of 3 independent experiments.  
 
Immunofluorescence Staining. Cells were fixed with 4% paraformaldehyde, permeabilized 
with 0.1% Triton X-100 and blocked with 10% swine serum for 1 hour at room temperature. 
Incubation with primary antibodies or Sma-Cy3 conjugated (sigma) was performed at 4℃ 
overnight, followed by incubation with secondary antibodies (corresponding fluorescent-
conjugated IgG antibodies, ThermoFisher) for 45 mins at 37℃. Cells were then counterstained 
with DAPI for 3 mins at room temperature and mounted with fluorescent mounting media 
(Dako). For 5hmc staining, a denaturation step (2N HCl for 15 min), followed by a 
neutralization step (100mM Tris-HCl pH 8,5 for 10 min) were added before blocking. 
Antibodies: 5hmc (Diagenode, pAb-HMC-050, rabbit polyclonal, 1/500), VEGFR2 (Cell 
signalling, 2479S, 1/50), Tet1 (Novus, NBP219290, 1/100), Tet2 (Bioss, bs-9449R, 1/100), 
Tet3 (Novus biologicals, NBP2-20602, 1/100), ETV2 (Santa cruz, sc-164278, 1/200), β-
catenin (Cell signalling, L87A12, 1/1000), Rasip1 (Proteintech, 17971-1, 1/200), IGFBP-5 
(Santa cruz, sc-13093, 1/100), COL1A (Santa cruz, sc-8784, 1/50). Images are 
representatives of at least 3 independent experiments.  
 
Hematoxylin and Eosin staining. Femoral arteries were fixed in 4% paraformaldehyde 
overnight. Later, the tissues were processed, embedded in paraffin, sectioned, and 5µM thick 
sections were processed for Hematoxylin and Eosin staining, Elastica Van Giesen staining or 
Immunohistochemistry. 
 
Immunohistochemistry. Briefly, sections were processed through xylene and alcohol series 
followed by antigen retrieval in citrate buffer, treated with 3% H2O2 for 20 min, blocked in 10% 
serum for 30 mins followed by incubation with cd31 (abcam, ab28364, 1/50), or PCNA (abcam, 
ab29, 1/100) antibodies overnight at 4°C. Later, the sections were washed (PBS), incubated 
with biotinylated secondary antibodies (vectorlabs, 1/100) for 30 min at RT before revelation, 
and counterstaining with hematoxylin and mounting. 
 
Statistics. Statistics were performed using Student’s t-test or One-way ANOVA with 
Bonferroni test.  
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GAPDH
ACTA2
PDGFRβ
CDH11
COL1A
CD34
TET1
TET2
TET3
CDH5
TIE2
FLK1
FLI1
EGFL7
RASIP1
ROBO4
POSTN
Flt1
IGFBP5 GCTCTTTTCGTTGAGGCAAACCCCCTGCGACGAGAAAGCTC
Quantitative RT PCR primers sequences
TCTGTGGAGTCAGCTTGCTCCTTT TGAGGGATGTTTCGGCATCAGACA
CGACTTCAACAGCAACTCCCACTCTTCC
TCCTGACGCTGAAGTATCCGAT
TGGGTGGTCCAGGGTTTCTTACTCCTT
GGCCACACGAAGCTCGTTATAG
CCTTCCGTACTCCCAAACTCAT
CACGGCTTCGAGGCAAGCCA CCCCGGTTCCCATCCCCCAT
AGGACAGCAACTTCACCCTCA AACTGCCCATACTTGACC
CGGAAGCTCTGATGATGTGA CTTCATGGAGGCCTTGG
CGCTGTGTCAATACTGTGGGA GTTCTAGCACATCAACCCGAG
TCATGGAGCAGCTTACGGACT GGGTGCGAGGAAAAACTTTCA
ACTCGGGGACCTATATGTGTATG
AAACATGGTCAATAGGCATCACTCCTGCCCTTATATGCTCTGCT
GGGATTCCTGGATAGACACCC
AGGAGTGATACCAGCTTTAGTCC CCGAGCAGGTCAGAACAAAGG
CCACAGACTTCCCCAACTG CAGGCCTAACCTCAGACTGG
CTGGGTCTGGAACCAATTCTTT GCCTGAGCCATCAGTGTGTA
GCTCCTCTTAGGGGCCACT CCACGTCTCACCATTGGG
GCAGTGAACCCCGGAAAAC AGAGCCATTGTAAACCCGTTG
GGGATGGTCCTTGCATCAGAA ACTGGTAGCCACTGGTCTGGTTG
CTCCTACATGCCTTCCTACC GTTTGGATAGATCCCAGCAG
AGAGAAGACAATCGAGAAGTCGG
